Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP.

Autor: Ospina AV; Head of the Oncology Department at the Hospital Universitario Puerta de Hierro. Full Professor of Medicine, Universidad Autónoma de Madrid, C/Manuel de Falla, 1 Majadahonda, 28222, Madrid, Spain. avospina@hotmail.com., Bolufer Nadal S; H. General Universitario Dr. Balmis de Alicante, Alicante, Spain., Campo-Cañaveral de la Cruz JL; Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain., González Larriba JL; H. Clínico San Carlos, Madrid, Spain., Macía Vidueira I; H. Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain., Massutí Sureda B; H. Universitario Dr Balmis Alicante, Alicante, Spain., Nadal E; ICO Bellvitge, Hospitalet, Barcelona, Spain., Trancho FH; H. Clínico San Carlos, Madrid, Spain., Álvarez Kindelán A; H. Reina Sofía, Córdoba, Spain., Del Barco Morillo E; H. Universitario de Salamanca, Salamanca, Spain., Bernabé Caro R; Hospital Virgen Del Rocio, Seville, Spain., Bosch Barrera J; ICO, H. Universitario Dr. Josep Trueta, Girona, Spain., Calvo de Juan V; Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain., Casal Rubio J; H. Universitario Alvaro Cunqueiro, Vigo, Spain., de Castro J; H. Universitario La Paz, Madrid, Spain., Cilleruelo Ramos Á; H. Clínico Universitario de Valladolid, Valladolid, Spain., Cobo Dols M; H. Regional Universitario Málaga, Malaga, Spain., Dómine Gómez M; H. Universitario Fundación Jiménez Díaz, Madrid, Spain., Figueroa Almánzar S; H. Clínico Universitario de Valencia, Valencia, Spain., Garcia Campelo R; H. Universitario A Coruña, A Coruña, Spain., Insa Mollá A; H. Clínico Universitario de Valencia, Valencia, Spain., Jarabo Sarceda JR; H. Clínico San Carlos, Madrid, Spain., Jiménez Maestre U; H. Universitario Cruces, Barakaldo, Bizkaia, Spain., López Castro R; H. Clínico Universitario de Valladolid, Valladolid, Spain., Majem M; H. de la Santa Creu i Sant Pau, Barcelona, Spain., Martinez-Marti A; H. Universitari Vall D'hebrón, Barcelona, Spain., Martínez Téllez E; H. de la Santa Creu i Sant Pau, Barcelona, Spain., Sánchez Lorente D; H. Clinic de Barcelona, Barcelona, Spain., Provencio M; Head of the Oncology Department at the Hospital Universitario Puerta de Hierro. Full Professor of Medicine, Universidad Autónoma de Madrid, C/Manuel de Falla, 1 Majadahonda, 28222, Madrid, Spain. mariano.provencio@uam.es.; Universidad Autónoma de Madrid, Ciudad Universitaria de Cantoblanco, 28049, Madrid, Spain. mariano.provencio@uam.es.
Jazyk: angličtina
Zdroj: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2024 Jul; Vol. 26 (7), pp. 1647-1663. Date of Electronic Publication: 2024 Mar 26.
DOI: 10.1007/s12094-024-03382-y
Abstrakt: Introduction: Recent advances in the treatment of locally advanced NSCLC have led to changes in the standard of care for this disease. For the selection of the best approach strategy for each patient, it is necessary the homogenization of diagnostic and therapeutic interventions, as well as the promotion of the evaluation of patients by a multidisciplinary oncology team.
Objective: Development of an expert consensus document with suggestions for the approach and treatment of locally advanced NSCLC leaded by Spanish Lung Cancer Group GECP.
Methods: Between March and July 2023, a panel of 28 experts was formed. Using a mixed technique (Delphi/nominal group) under the guidance of a coordinating group, consensus was reached in 4 phases: 1. Literature review and definition of discussion topics 2. First round of voting 3. Communicating the results and second round of voting 4. Definition of conclusions in nominal group meeting. Responses were consolidated using medians and interquartile ranges. The threshold for agreement was defined as 85% of the votes.
Results: New and controversial situations regarding the diagnosis and management of locally advanced NSCLC were analyzed and reconciled based on evidence and clinical experience. Discussion issues included: molecular diagnosis and biomarkers, radiologic and surgical diagnosis, mediastinal staging, role of the multidisciplinary thoracic committee, neoadjuvant treatment indications, evaluation of response to neoadjuvant treatment, postoperative evaluation, and follow-up.
Conclusions: Consensus clinical suggestions were generated on the most relevant scenarios such as diagnosis, staging and treatment of locally advanced lung cancer, which will serve to support decision-making in daily practice.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: